[Cardiac Amyloidosis Registry in Santiago, Chile (RAMICAR): Three-Year Follow-Up Results].
J, Á.G., F, V.T., J, J.M., F, A.F., C, P.O., M, D.A., R, J.F., A, R.F., M, L.V., & P, M.M. (2026). [Cardiac Amyloidosis Registry in Santiago, Chile (RAMICAR): Three-Year Follow-Up Results].. Revista medica de Chile. https://doi.org/10.4067/s0034-98872026000400508
J ÁG, F VT, J JM, F AF, C PO, M DA, et al. [Cardiac Amyloidosis Registry in Santiago, Chile (RAMICAR): Three-Year Follow-Up Results].. Revista medica de Chile. 2026; doi: 10.4067/s0034-98872026000400508
J ÁG, F VT, J JM, et al. [Cardiac Amyloidosis Registry in Santiago, Chile (RAMICAR): Three-Year Follow-Up Results].[J]. Revista medica de Chile. 2026. DOI: 10.4067/s0034-98872026000400508.
@article{j2026,
author = {Álvarez G J and Verdugo T F and Jalil M J and Appiani F F and Peña O C and Duarte A M and Jaimovich F R and Rojas F A and Llancaqueo V M and McNab M P},
title = {[Cardiac Amyloidosis Registry in Santiago, Chile (RAMICAR): Three-Year Follow-Up Results].},
journal = {Revista medica de Chile},
year = {2026},
doi = {10.4067/s0034-98872026000400508},
note = {PMID: 42441675},
}
TY - JOUR AU - Álvarez G J AU - Verdugo T F AU - Jalil M J AU - Appiani F F AU - Peña O C AU - Duarte A M AU - Jaimovich F R AU - Rojas F A AU - Llancaqueo V M AU - McNab M P TI - [Cardiac Amyloidosis Registry in Santiago, Chile (RAMICAR): Three-Year Follow-Up Results]. T2 - Revista medica de Chile PY - 2026 DO - 10.4067/s0034-98872026000400508 AN - PMID:42441675 ER -
UNLABELLED: Cardiac amyloidosis (CA) is characterized by extracellular protein deposition, generating ventricular hypertrophy, heart failure and arrhythmias. The main proteins involved are light chains (CA-AL) and transthyretin (CA-TTR). AIM: To describe clinical, imaging and biochemical characteristics of patients with CA, their prognosis and access to specific therapies for each etiology. METHODS: Prospective multicenter registry of patients >50 years old with red flags for CA, such as left ventricular hypertrophy (septum >12 mm) associated to: restrictive filling; aortic stenosis; low voltage, pseudoinfarction pattern in electrocardiogram (ECG), heart failure with NT-proBNP >600 pg/ml, elevated troponins, carpal tunnel, polyneuropathy, compatible cardioresonance. RESULTS: 60 patients were included, 37 men, age 68±13 years; 36 AC-AL; 24 CA-TTR (10 patients CA-TTR mutated). The most frequent red flags were: strain pattern or global longitudinal deformation (97%), heart failure (95%), restrictive filling (72%), compatible cardioresonance (85%), pseudoinfarction in ECG (62%), elevated troponins (75%). CA-TTR patients were older, greater prevalence of atrial fibrillation and atrioventricular block; larger septal thickness (17.0±0.45 versus 14.7±2.5 mm) and left atrial volume (55±13 versus 42±8 ml/m2). CA-AL patients showed larger troponin elevation. There were no differences in systolic function, left ventricular deformation or NT-proBNP. There were no differences in mortality. CA-AL patients had greater access to specific therapies (87% versus 17%). CONCLUSIONS: Patients with CA presented moderate/severe hypertrophy, restrictive filling, atrial dilatation and biomarker elevation, suggestive of late diagnosis of CA. Mortality between groups was similar, with greater access to specific therapies in CA-AL.